Yucai Wang, MD, PHD
NPI: 1174866016
Total Payments
$1.1M
2024 Payments
$600,577
Companies
15
Transactions
84
Medicare Patients
666
Medicare Billing
$98,234
Payment Breakdown by Category
Research$1.0M (93.4%)
Consulting$47,469 (4.3%)
Travel$19,927 (1.8%)
Other$2,625 (0.2%)
Food & Beverage$1,865 (0.2%)
Education$834.25 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 3 | 93.4% |
| Consulting Fee | $47,469 | 20 | 4.3% |
| Travel and Lodging | $19,927 | 26 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,625 | 1 | 0.2% |
| Food and Beverage | $1,865 | 33 | 0.2% |
| Education | $834.25 | 1 | 0.1% |
Payments by Type
Research
$1.0M
3 transactions
General
$72,720
81 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1.0M | 4 | $0 (2024) |
| Kite Pharma, Inc. | $24,745 | 25 | $0 (2023) |
| Gilead Sciences, Inc. | $18,450 | 7 | $0 (2022) |
| ABBVIE INC. | $7,603 | 20 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $6,221 | 6 | $0 (2023) |
| Lilly USA, LLC | $5,187 | 6 | $0 (2024) |
| Incyte Corporation | $4,053 | 3 | $0 (2021) |
| Genmab U.S., Inc. | $2,714 | 6 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $1,515 | 1 | $0 (2022) |
| F. Hoffmann-La Roche AG | $158.67 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $600,577 | 20 | Eli Lilly and Company ($594,197) |
| 2023 | $456,325 | 26 | Eli Lilly and Company ($435,600) |
| 2022 | $39,115 | 25 | Gilead Sciences, Inc. ($18,450) |
| 2021 | $6,274 | 8 | Incyte Corporation ($4,053) |
| 2019 | $125.00 | 1 | Pharmacyclics LLC, An AbbVie Company ($125.00) |
| 2018 | $188.88 | 2 | Kite Pharma, Inc. ($113.88) |
| 2017 | $70.42 | 2 | Genentech USA, Inc. ($39.57) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $158.67 | Research |
| Study: LEO DLBCL R R | ||||||
| 12/08/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $136.68 | General |
| Category: Oncology | ||||||
| 09/26/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $362.50 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $106.45 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $105.86 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $33.00 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $438.31 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $291.15 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $66.99 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $420.20 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $88.40 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $83.88 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $8.82 | General |
| Category: ONCOLOGY | ||||||
| 04/15/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $337.87 | General |
| Category: ONCOLOGY | ||||||
| 04/15/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $81.23 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $594,196.85 | Research |
| Study: A PHASE 2 STUDY OF MRD GUIDED FIXED DURATION THERAPY FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH LOXO-305 AND VENETOCLAX | ||||||
| 01/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2023 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $2,390.00 | General |
| Category: CELLT | ||||||
| 12/09/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $117.31 | General |
| 11/27/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $435,599.89 | Research |
| Study: A PHASE 2 STUDY OF MRD GUIDED FIXED DURATION THERAPY FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH LOXO-305 AND VENETOCLAX | ||||||
| 11/07/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 11/01/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF MRD GUIDED FIXED DURATION THERAPY FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH LOXO-305 AND VENETOCLAX | Eli Lilly and Company | $1.0M | 2 |
| LEO DLBCL R R | F. Hoffmann-La Roche AG | $158.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 190 | 336 | $114,231 | $29,541 |
| 2022 | 4 | 135 | 236 | $91,894 | $23,044 |
| 2021 | 6 | 156 | 279 | $29,872 | $22,199 |
| 2020 | 6 | 185 | 325 | $34,137 | $23,451 |
Total Patients
666
Total Services
1,176
Medicare Billing
$98,234
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 35 | 100 | $35,849 | $9,289 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 85 | $24,486 | $7,526 | 30.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 92 | $25,484 | $5,657 | 22.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $15,075 | $4,325 | 28.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $6,446 | $1,113 | 17.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,876 | $1,059 | 27.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 11 | $3,014 | $572.55 | 19.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 115 | $40,710 | $9,174 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 79 | $22,910 | $7,066 | 30.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $12,060 | $3,406 | 28.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $16,214 | $3,397 | 21.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 72 | $9,597 | $6,971 | 72.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 84 | $8,684 | $6,773 | 78.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 28 | 69 | $5,012 | $3,721 | 74.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 21 | $2,768 | $2,222 | 80.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $2,623 | $1,965 | 74.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 16 | 21 | $1,189 | $546.48 | 46.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 59 | 121 | $14,785 | $9,788 | 66.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 30 | 30 | $6,170 | $4,570 | 74.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 29 | 55 | $4,128 | $3,128 | 75.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 29 | 71 | $3,780 | $2,100 | 55.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 15 | 25 | $2,713 | $2,080 | 76.7% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 23 | 23 | $2,562 | $1,785 | 69.7% |
About Yucai Wang, MD, PHD
Yucai Wang, MD, PHD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2013. The National Provider Identifier (NPI) number assigned to this provider is 1174866016.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Yucai Wang, MD, PHD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $600,577 received in 2024. These payments were reported across 84 transactions from 15 companies. The most common payment nature is "" ($1.0M).
As a Medicare-enrolled provider, Wang has provided services to 666 Medicare beneficiaries, totaling 1,176 services with total Medicare billing of $98,234. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Rochester, MN
- Active Since 03/28/2013
- Last Updated 08/21/2020
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1174866016
Products in Payments
- Tecartus (Drug) $27,084
- VENCLEXTA (Drug) $6,583
- CALQUENCE (Drug) $6,091
- Epkinly (Drug) $2,714
- IMBRUVICA (Drug) $1,515
- EPKINLY (Drug) $1,020
- Yescarta (Drug) $183.69
- JAYPIRCA (Drug) $136.68
- Imbruvica (Drug) $125.00
- BRUKINSA (Drug) $86.47
- Cabometyx (Drug) $75.00
- RYDAPT (Drug) $30.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Rochester
Kevin Perry, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $675,526
Student in an Organized Health Care Education/Training Program $675,526
Arjun Sebastian, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $132,513
Student in an Organized Health Care Education/Training Program $132,513
Benjamin Tracy
Student in an Organized Health Care Education/Training Program — Payments: $112,594
Student in an Organized Health Care Education/Training Program $112,594
Dr. Vijay Agarwal, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $105,512
Student in an Organized Health Care Education/Training Program $105,512
Mr. Timothy Brown, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $89,868
Student in an Organized Health Care Education/Training Program $89,868
Dr. Brenda Tesini, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $39,532
Student in an Organized Health Care Education/Training Program $39,532